Document:

Executive Change in Control Severance Benefits Agreement

 EXHIBIT 10.02 
 EXECUTIVE 
 CHANGE IN CONTROL 
 SEVERANCE BENEFITS AGREEMENT 
 THIS EXECUTIVE CHANGE IN CONTROL SEVERANCE
BENEFITS AGREEMENT (the “AGREEMENT”) is entered into on April 2, 2007, between David B. Bell (“Executive”) and INTERSIL CORPORATION, a Delaware corporation (the “COMPANY”). 
 WHEREAS, this Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific
events after the date hereof. 
 NOW THEREFORE, The Company and Executive hereby agree as follows: 
 Certain capitalized terms used in this Agreement are defined in Article VI. 
 ARTICLE I 
 EMPLOYMENT BY THE COMPANY 
 1.1 Executive is currently employed as an executive of the Company. 
 1.2 This Agreement shall remain in full force and effect so long as Executive is employed by the Company or its subsidiaries; provided, however, that the rights and obligations of the parties hereto contained
in Articles II through VII shall survive Two and One Half (2-1/2) years following a Covered Termination (as hereinafter defined). 
 1.3
The Company and Executive wish to set forth the compensation and benefits which Executive shall be entitled to receive if Executive’s employment with the Company terminates following a Change in Control under the circumstances described in
Article II of this Agreement. 
 1.4 The duties and obligations of the Company to Executive under this Agreement shall be in
consideration for Executive’s continued employment with the Company and Executive’s execution of the general waiver and release described in Section 3.2. 
 ARTICLE II 
 SEVERANCE BENEFIT 
 2.1 Entitlement To Severance Benefits. If Executive’s employment terminates due to an Involuntary Termination or a Voluntary Termination for
Good Reason (as hereinafter defined) within twelve (12) months following the effective date of a Change in Control, the termination of employment will be a Covered Termination and the Company shall pay Executive the compensation and benefits
described in this Article II. If Executive’s employment terminates, but not due to an Involuntary Termination or a Voluntary Termination for Good Reason within twelve (12) months following the effective date of a Change in Control, then
the termination of employment will not be a Covered Termination and Executive will not be entitled to receive any payments or benefits under this Article II. 

 Payment of any benefits described in this Article II shall be subject to the restrictions and limitations
set forth in Article III of this Agreement. 
 2.2 Severance Payments. The Company shall continue to pay the Executive’s Annual
Base Pay and full target Annual Bonus (without regard to satisfaction of any target performance objectives) for two years (the “Severance Period”) (less applicable deductions and withholdings) payable in accordance with
Intersil’s normal payroll practices immediately prior to the Covered Termination. 
 2.3 Welfare Benefits. Following a Covered
Termination, Executive and his covered dependents will be eligible to continue their Welfare Benefits coverage under any Welfare Benefits plan or program maintained by the Company on the same terms and conditions (including cost to Executive) as in
effect immediately prior to the Covered Termination, for a period of one (1) year following the Covered Termination. 
 With respect to
any Welfare Benefits provided through an insurance policy, the Company’s obligation to provide such Welfare Benefits following a Covered Termination shall be limited by the terms of such a policy; provided that (i) the Company shall make
reasonable efforts to amend such policy to provide the continued coverage described in this Section 2.3, and (ii) if a policy providing health benefits is not amended to provide the continued benefits described in this Section 2.3,
the Company shall pay for the cost of comparable replacement coverage (or Medigap insurance if Executive qualifies for Medicare) until the end of the one (1) year period following the Covered Termination. 
 The Company shall reimburse Executive for any income tax liability due as a result of the provision of Welfare Benefits under this Article II (and as a
result of any payments due under this paragraph) in order to put Executive in the same after-tax position as if no taxable Welfare Benefits had been provided. 
 This Section 2.3 is not intended to affect, nor does it affect, the rights of Executive, or Executive’s covered dependents, under any applicable law with respect to health insurance continuation coverage.

 2.4 Mitigation. Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount
of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another
employer or by retirement benefits after the date of the Covered Termination, or otherwise. 
 2.5 409A Compliance. If any payments
due under this Agreement would subject Executive to any penalty tax imposed under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) if such payments were made at the time as required herein, then the payments
that cause the imposition such penalty tax shall be payable in one lump sum on the first day which is at least six months after the date of Executive’s separation of service as set forth in Section 409A of the Code and the regulations and
other official guidance thereunder. 
  

 - 2 - 

 ARTICLE III 
 LIMITATIONS AND CONDITIONS ON BENEFITS 
 3.1 Withholding of Taxes. The Company shall withhold
appropriate federal, state or local income and employment taxes from any payments hereunder. 
 3.2 Employee Agreement and Release Prior
to receipt of Benefits. Upon the occurrence of a Covered Termination, and prior to the receipt of any benefits under this Agreement on account of the occurrence of a Covered Termination, Executive shall, as of the date of a Covered Termination,
execute an employee agreement and release in the form attached hereto as Exhibit A. Such employee agreement and release shall specifically relate to all of Executive’s rights and claims in existence at the time of such execution and
shall confirm Executive’s obligations under the Company’s standard form of proprietary information agreement. It is understood such employee release and agreement shall comply with applicable law. In the event Executive does not execute
such release and agreement within the period required by applicable law, or if Executive revokes such employee agreement and release within the period permitted by applicable law, no benefits shall be payable under this Agreement and this Agreement
shall be null and void. 
 ARTICLE IV 
 OTHER RIGHTS AND BENEFITS 
 4.1 Nonexclusivity. Nothing in this Agreement shall prevent or
limit Executive’s continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or
otherwise affect such rights as Executive may have under any stock option or other agreements with the Company. Except as otherwise expressly provided herein, amounts which are vested benefits or which Executive is otherwise entitled to receive
under any plan, policy, practice or program of the Company at or subsequent to the date of a Covered Termination shall be payable in accordance with such plan, policy, practice or program. 
 4.2 Parachute Payments. If all or any portion of the amounts payable or benefits provided to the Executive under this Agreement or otherwise are
‘excess parachute payments’ and are subject to the excise tax imposed by Section 4999 of the Code (the ‘Excise Tax’), and if the net after-tax amount (taking into account all applicable taxes payable by the Executive,
including without limitation any Excise Tax) that the Executive would receive with respect to such payments or benefits does not exceed the net after-tax amount the Executive would receive if the amount of such payments and benefits were reduced to
the maximum amount which could otherwise be payable to the Executive without the imposition of the Excise Tax, then, only the extent necessary to eliminate the imposition of the Excise Tax, such payments and benefits shall be reduced, in the order
and of the type mutually agreed to by the Executive and the Company. The calculations required under this Section 4.2 shall be prepared by the Company and reviewed for accuracy by the Executive and the Company’s regular certified public
accountantse. 
  

 - 3 - 

 ARTICLE V 
 NON-ALIENATION OF BENEFITS 
 No benefit hereunder shall be subject to anticipation, alienation, sale,
transfer, assignment, pledge, encumbrance or charge, and any attempt to so subject a benefit hereunder shall be void. 
 ARTICLE VI

 DEFINITIONS 
 For
purposes of the Agreement, the following terms shall have the meanings set forth below: 
 6.1 “Agreement” means this
Executive Change in Control Severance Benefits Agreement. 
 6.2 “Annual Base Pay” means Executive’s annual base pay at
the rate in effect during the last regularly scheduled payroll period immediately preceding (i) the Change in Control or (ii) the Covered Termination, whichever is greater. 
 6.3 “Annual Bonus” means the Executive’s projected or estimated annual cash incentive bonus at target for the fiscal year of the
Company in which termination of Executive’s employment occurs. 
 6.4 “Change in Control” means the consummation of any
of the following transactions after the date hereof: 
 (a) the stockholders of the Company approve a merger or consolidation of the
Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted
into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or
the stockholders of the Company approve a plan of liquidation or dissolution of the Company or an agreement for the sale, lease, exchange or other transfer or disposition by the Company of all or substantially all (more than fifty percent
(50%)) of the Company’s assets; 
 (b) any person (as such term is used in Sections 13(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”)), is or becomes the beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) directly or indirectly of 25% or more of the Company’s outstanding Common Stock; or 
  

 - 4 - 

 (c) a change in the composition of the Board of Directors of the Company within a three
(3) year period, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either: 
 (A) are directors of the Company as of the date hereof; 
 (B) are elected, or nominated for election, to the Board of Directors of the Company with the affirmative votes of at least a majority of the directors of the Company who are Incumbent Directors described in
(A) above at the time of such election or nomination; or 
 (C) are elected, or nominated for election, to the Board of
Directors of the Company with the affirmative votes of at least a majority of the directors of the Company who are Incumbent Directors described in (A) or (B) above at the time of such election or nomination. 
 Notwithstanding the foregoing, “Incumbent Directors” shall not include an individual whose election or nomination is in connection with an
actual or threatened proxy contest relating to the election of directors to the Company. 
 6.5 “Company” means Intersil
Corporation, a Delaware corporation, and any successor thereto. 
 6.6 “Covered Termination” means an Involuntary
Termination or a Voluntary Termination for Good Reason within twelve (12) months following a Change in Control after the date hereof. No other event shall be a Covered Termination for purposes of this Agreement. 
 6.7 “Date of Covered Termination” means the first date following the last date of Executive’s employment with the Company or its
subsidiaries as a result of a Covered Termination. 
 6.8 “Date of Notice of Termination” means the date the Executive is
given notice, either verbal or written, that his employment with the Company or its subsidiaries has been or will be terminated. 
 6.9
“Involuntary Termination” means Executive’s dismissal or discharge by the Company or its subsidiaries (or, if applicable, by the successor entity) for reasons other than fraud, misappropriation or embezzlement on the part of
Executive which resulted in material loss, damage or injury to the Company. Notwithstanding the foregoing, Executive shall not be deemed to have been terminated for one of these reasons unless and until there shall have been delivered to Executive a
copy of a resolution, duly adopted by the affirmative vote of not less than three-quarters of the entire membership of the Company’s Board of Directors at a meeting of the Board called and held for the purpose (after reasonable notice to
Executive and an opportunity for the Executive, together with Executive’s counsel, to be heard before the Board of Directors), finding that in the good faith opinion of the Board of Directors, Executive was guilty of conduct set forth in the
immediately preceding sentence and specifying the particulars thereof in detail. 
  

 - 5 - 

 The termination of an Executive’s employment would not be deemed to be an “Involuntary
Termination” if such termination occurs as a result of the death or disability of Executive. 
 6.10 “Voluntary Termination for
Good Reason” means that the Executive voluntarily terminates his employment after any of the following are undertaken without Executive’s express written consent: 
 (a) the assignment to Executive of any duties or responsibilities which result in any diminution or adverse change of Executive’s position,
status or circumstances of employment as in effect immediately prior to the Change in Control of the Company; any removal of Executive from or any failure to reelect Executive to any of such positions, except in connection with the termination of
his employment for death, disability, retirement, fraud, misappropriation, embezzlement or any other voluntary termination of employment by Executive other than Voluntary Termination for Good Reason; 
 (b) a reduction by the Company in Executive’s Annual Base Pay or targeted annual cash incentive bonus in effect at the time; 
 (c) any failure by the Company to continue in effect any benefit plan or arrangement, including incentive plans or plans to receive securities of
the Company, in which Executive is participating at the time of the Change in Control of the Company (hereinafter referred to as “Benefit Plans”), or the taking of any action by the Company which would adversely affect Executive’s
participation in or reduce Executive’s benefits under any Benefit Plans or deprive Executive of any fringe benefit enjoyed by Executive at the time of the Change in Control of the Company, provided, however, that Executive may not terminate
employment with the Company for Good Reason following a Change in Control of the Company if the Company offers a range of benefit plans and programs which, taken as a whole, are comparable to the Benefit Plans as determined in good faith by
Executive; 
 (d) a relocation of Executive, or the Company’s principal executive offices if Executive’s principal office is
at such offices, to a location more than fifteen (15) miles from the location at which Executive performed Executive’s duties immediately prior to the Change in Control of the Company, except for required travel by Executive on the
Company’s business to an extent substantially consistent with Executive’s business travel obligations at the time of the Change in Control of the Company; 
 (e) any breach by the Company of any provision of this Agreement; or 
 (f) any failure by the
Company to obtain the assumption of this Agreement by any successor or assign of the Company. 
 6.11 “Welfare Benefits”
means benefits providing for coverage or payment in the event of Executive’s death, disability, illness or injury that were provided to Executive immediately before a Change in Control, whether taxable or non-taxable and whether funded through
insurance or otherwise, including without limitation all life and health insurance coverage. 
  

 - 6 - 

 ARTICLE VII 
 GENERAL PROVISIONS 
 7.1 Employment Status. This Agreement does not constitute a contract of
employment or impose on Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee, or (iii) to
change the Company’s policies regarding termination of employment. 
 7.2 Notices. Any notices provided hereunder must be in
writing and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by telex or facsimile) or the third day after mailing by first class mail, to the Company at its
primary office location and to Executive at his address as listed in the Company’s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at his
address as listed in the Company’s payroll records. 
 7.3 Severability. Whenever possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such
invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had
never been contained herein. 
 7.4 Waiver. If either party should waive any breach of any provisions of the Agreement, he or it shall
not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 
 7.5
Complete Agreement. This Agreement, including Exhibit A and other written agreements referred to in this Agreement, constitutes the entire agreement between Executive and the Company and it is the complete, final, and exclusive embodiment
of their agreement with regard to the subject matter hereof, and expressly supersedes all other agreements, promises or understandings, whether oral or written. For avoidance of doubt, the parties hereto acknowledge and agree that in the event of
any termination of Executive’s employment with the Company which constitutes a Covered Termination hereunder, Executive shall be entitled to the rights and benefits provided for in this Agreement in lieu of any rights or benefits provided for
in his employment agreement with the Company. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein. 
 7.6 Amendment or Termination of Agreement. This Agreement may be changed or terminated only upon the mutual written consent of the Company and
Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company after such change or termination has been approved by the Compensation Committee of the Company’s
Board of Directors. 
  

 - 7 - 

 7.7 Counterparts. This Agreement may be executed in separate counterparts, any one of which need
not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. 
 7.8
Headings. The headings of the Articles and sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 7.9 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and
their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and Executive may not assign any of his rights hereunder without the written consent of the Company, which
consent shall not be withheld unreasonably. 
 7.10 Attorneys’ Fees. If Executive brings any action to enforce his rights
hereunder, Executive shall be entitled to recover his reasonable attorneys’ fees and costs incurred in connection with such action if Executive is the prevailing party in such action. 
 7.11 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the
State of California. 
 7.12 Non-Publication. The parties mutually agree not to disclose publicly the terms of this Agreement except
to the extent that disclosure is mandated by applicable law. 
 7.13 Construction of Agreement. In the event of a conflict between the
text of this Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control. 
 [Signatures Appear on the Following Page] 
  

 - 8 - 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year written above. 
  

					
	 INTERSIL CORPORATION
 a Delaware
Corporation
	 		 	EXECUTIVE
			
	  
	 		 	  

	Richard M. Beyer	 		 	Name: David B. Bell
	Chief Executive Officer	 		 	Title: President and Chief Operating Officer

 Exhibit A: Employee Agreement and Release 

 Exhibit A 
 Intersil Corporation 
 Employee Agreement and Release 
 I understand and agree completely to the terms set forth in the foregoing agreement. 
 I hereby confirm my obligations under the Company’s standard form of proprietary information agreement. 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not
extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected this settlement with the debtor.” I hereby expressly waive and
relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company. 
 Except as otherwise set forth in this Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their
officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of
every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment
with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the Effective Date of this Agreement, including but not limited to: all such claims and demands directly or indirectly
arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for
personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of
compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended
(“ADEA”); the federal American with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the
implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to provide you with continued coverage under the Company’s directors and
officers liability insurance policy to the same extent that it has provided such coverage to previously departed officers and directors of the Company. 

 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA.
I also acknowledge that the consideration given for the waiver and release in the preceding paragraph hereof is in addition to anything of value which I was already entitled. I further acknowledge that I have been advised by this writing, as
required by the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise after the Effective Date of this Agreement; (b) I have the right to consult with an attorney prior to executing this Agreement;
(c) I have twenty-one (21) days to consider this Agreement (although I may choose to voluntarily execute this Agreement earlier); (d) I have seven (7) days following the execution of this Agreement by the parties to revoke the
Agreement; and (e) this Agreement shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day after this Agreement is executed by me, provided that the Company has also executed this
Agreement by that date (“Effective Date”). 
  

			
	By:	 	  

		 	David B. Bell
		
	Date:Third Amended and Restated Investor Rights Agreement

 Exhibit 4.2 
 DEVAX, INC. 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 October 21, 2005 

 DEVAX, INC. 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS THIRD AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 21st day of October, 2005, by and among DEVAX, INC., a Delaware corporation (the “Company”), the holders of shares of the Company’s Common Stock listed
on Exhibit A attached hereto (each a “Common Holder” and, collectively, the “Common Holders”), the investors listed on Exhibit B attached hereto (the “Investors”) and Occam International B.V.
(“Occam”) and Roberts Mitani, LLC (“Roberts Mitani”), each a holder of warrants to purchase shares of the Company’s Common Stock (the “Warrant Holders”). 
 RECITALS 
 WHEREAS, certain of the Investors (the “Series D
Investors”) are purchasing shares of the Company’s Series D Preferred Stock (the “Series D Preferred Stock”), pursuant to that certain Series D Preferred Stock Purchase Agreement (the “Purchase
Agreement”) of even date herewith (the “Financing”); 
 WHEREAS, the obligations in the Purchase Agreement are
conditioned upon the execution and delivery of this Agreement; 
 WHEREAS, certain of the Investors (the “Prior Investors”)
are holders of the Company’s Series C Preferred Stock (the “Series C Preferred Stock”), Series B Preferred Stock (the “Series B Preferred Stock”) and Series A Preferred Stock (the “Series A Preferred
Stock” and together with, the Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock shall be referred to herein collectively as the “Preferred Stock”); 
 WHEREAS, the Prior Investors and the Company are parties to that Second Amended and Restated Investor Rights Agreement, dated March 26, 2004
(the “Prior Agreement”); 
 WHEREAS, the Warrant Holders have each executed a form of Joinder to the Prior Agreement and
have become parties thereto; 
 WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept
the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; and 
 WHEREAS, in connection with
the consummation of the Financing, the Company and the Investors have agreed to the registration rights, information rights, and other rights as set forth below. 
 NOW, THEREFORE, in consideration of these premises and for other good and valid consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1. GENERAL 
 1.1 Definitions. As
used in this Agreement the following terms shall have the following respective meanings: 
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended. 

 “Form S-3” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 “Holder” means any person owning of record Registrable Securities that have not been sold to the public or any assignee of record
of such Registrable Securities in accordance with Section 2.10 hereof. 
 “Initial Offering” means the
Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act. 
 “Major Investor” means any Holder of Series D Preferred Stock, Series C Preferred Stock or Series B Preferred Stock. 
 “Register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the
Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 
 “Registrable
Securities” means (a) Common Stock of the Company issued or issuable upon conversion of the Shares; (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or option,
other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities; (c) any Common Stock of the Company held by the Common Holders; (d) any Common
Stock of the Company issued, or issuable, upon the exercise of the warrants held by the Warrant Holders and (e) any Common Stock of the Company issued, or issuable, upon exercise of the warrants held by the Investors and their permitted
assigns. Notwithstanding the foregoing, Registrable Securities shall not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144 under the Securities Act, or (ii) sold in a
private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned. 
 “Registrable
Securities then outstanding” shall be the number of shares determined by calculating the total number of shares of the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or
(b) are issuable pursuant to then exercisable or convertible securities. 
 “Registration Expenses” shall mean
all expenses incurred by the Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and
disbursements not to exceed Thirty Thousand Dollars ($30,000) of a single special counsel for the Holders, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the
compensation of regular employees of the Company which shall be paid in any event by the Company). 
 “SEC” or
“Commission” means the Securities and Exchange Commission. 
  

 2 

 “Securities Act” shall mean the Securities Act of 1933, as amended. 

“Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale. 
 “Series C Investor” shall mean an Investor holding shares of Series C Preferred Stock. 
 “Shares” shall mean the Preferred Stock held by the Investors listed on Exhibit B attached hereto and their permitted
assigns. 
 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 
 2.1 Restrictions On Transfer. 
 (a) Each Holder agrees not to make any disposition of all or
any portion of the Shares or Registrable Securities unless and until: 
 (i) There is then in effect a registration statement under
the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (ii) (A) The transferee has agreed in writing to be bound by the terms of this Agreement, (B) such Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such
disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 except in unusual circumstances. From and after
such time as the Company becomes a reporting company under Section 13 or Section 15 of the Exchange Act, the Company will not require a transferee of Shares or Registrable Securities to agree to be bound by the terms of this Agreement.

 Notwithstanding the provisions of paragraphs (i) and (ii) above, no such registration statement or opinion of counsel shall be necessary for a
transfer by a Holder which is (A) a partnership to its partners or former partners in accordance with partnership interests, (B) a corporation to its stockholders in accordance with their interest in the corporation, (C) a limited
liability company to its members or former members in accordance with their interest in the limited liability company, or (D) to the Holder’s affiliates, related funds or family members or trust for the benefit of an individual Holder;
provided that in each case the transferee will be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 
 (b) Each certificate representing Shares or Registrable Securities shall (unless otherwise permitted by the provisions of the Agreement) be stamped or otherwise imprinted with a legend substantially similar to
the following (in addition to any legend required under applicable state securities laws, the Company’s Bylaws, or as provided elsewhere in this Agreement): 
 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED 

  

 3 

 
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED OPINION OF COUNSEL SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 (c) The Company shall be obligated to reissue promptly unlegended
certificates at the request of any holder thereof if the holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of
may lawfully be so disposed of without registration, qualification or legend. 
 (d) Any legend endorsed on an instrument pursuant to
applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 
 2.2 Requested Registration. 
 (a) Request for Registration. Subject to the conditions of this Section 2.2, at any time after October 21, 2008, if an Initial Offering has not occurred, the holders of fifty percent (50%) of the Registrable
Securities held by the Series D Investors and the Series C Investors, in the aggregate, will have the right to have the Company effect one (1) registration of their Shares on Form S-1 pursuant to this Section 2.2 and at any time following
180 days after the Company’s Initial Offering, the holders of the Shares, by action of the holders of a majority of the Registrable Securities, will be entitled to have the Company effect three (3) registrations on Form S-1 pursuant to
this Section 2.2 (in each instance, the “Initiating Holders”). 
 (b) Notices; Company Action. In the case of
each requested registration contemplated by Section 2.2(a), if the Company shall receive from Initiating Holders a written request that the Company effect any registration, qualification or compliance with respect to shares of Registrable
Securities, provided that the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed three million dollars ($3,000,000) the Company will: 
 (i) promptly give written notice of the proposed registration, qualification or compliance to all other Holders then entitled to such a requested
registration; and 
 (ii) as soon as practicable, use its best efforts to effect such registration, qualification or compliance
(including, without limitation, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or
regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities
of any Holder or Holders then entitled to such a requested registration joining in such request as are specified in a written request received by the Company within twenty (20) days after receipt of such written notice from the Company.

 (c) Limitations. Notwithstanding the foregoing, the Company shall not be obligated to take any action pursuant to this
Section 2.2: 
 (i) In any particular jurisdiction in which the Company would be required to execute a general consent to service
of process in effecting such registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 
  

 4 

 (ii) During the period starting with the date sixty (60) days prior to the Company’s
estimated date of filing of, and ending on the date one hundred eighty (180) days immediately following the effective date of, any registration statement subject to Section 2.3 hereof (other than a registration of securities in a
Rule 145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; 
 (iii) If the Company shall furnish to such Initiating Holders a certificate signed by the President of the Company stating that in the good faith
judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future, then the Company’s obligation to use its best efforts to register, qualify or
comply under this Section 2.2 shall be deferred for a period not to exceed one hundred twenty (120) days from the date of receipt of written request from the Initiating Holders, provided that the Company may not exercise this
deferral right more than once per twelve (12) month period; or 
 (iv) If such registration, qualification or compliance is not
proposed to be part of a firm commitment underwritten public offering with underwriters reasonably acceptable to the Company. 
 Subject to the foregoing
clauses (i) through (iv), the Company shall file a registration statement covering the Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. 

(d) Underwriting. In the event of a registration pursuant to Section 2.2, the Company shall advise the Holders entitled to and as
part of the notice given pursuant to Section 2.2(b)(i) that the right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such Holder’s participation in the underwriting arrangements required by this
Section 2.2, and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested shall be limited to the extent provided herein. 
 The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in
customary form with the managing underwriter selected for such underwriting by the Holders of a majority of all Registrable Securities held by the Initiating Holders, but subject to the Company’s reasonable approval. Notwithstanding any other
provision of this Section 2.2, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders entitled
to include their Registrable Securities in such registration and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all such Holders (including the Initiating Holders) in
proportion, as nearly as practicable, to the respective total purchase prices paid to the Company for such Registrable Securities held by such Holders (including the Initiating Holders) at the time of filing the registration statement. No
Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such 

  

 5 

 
registration. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares
allocated to any Holder to the nearest one hundred (100) shares. 
 If any Holder disapproves of the terms of the underwriting, such
person may elect to withdraw therefrom by written notice to the Company, the managing underwriter and the Initiating Holders. The Registrable Securities and/or other securities so withdrawn shall also be withdrawn from registration, and such
Registrable Securities shall not be transferred in a public distribution prior to one hundred eighty (180) days after the effective date of such registration, or such other shorter period of time as the underwriters may require. 
 2.3 Piggyback Registrations. The Company shall notify all Holders in writing at least twenty (20) days prior to the filing of any and
all registration statements under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding
registration statements relating to employee benefit plans or with respect to corporate reorganizations or other transactions under Rule 145 of the Securities Act) and will afford each such Holder an opportunity to include in such registration
statement all or part of such Registrable Securities held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within fifteen (15) days after the
above-described notice from the Company, so notify the Company in writing. Such notice shall state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities
in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the
Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 
 (a) Underwriting. If
the registration statement under which the Company gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders. In such event, the right of any such Holder to be included in a registration
pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing
to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other provision
of the Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first, to the
Company; second, to the Holders on a pro rata basis based on the total purchase price paid to the Company for the Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis. No
such reduction shall (i) reduce the securities being offered by the Company for its own account to be included in the registration and underwriting or (ii) reduce the amount of securities of the selling Holders included in the registration
below twenty-five percent (25%) of the total amount of securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in which event any or
all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding sentence. 
 (b)
Right To Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 prior to the effectiveness 

  

 6 

 
of such registration whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn
registration shall be borne by the Company in accordance with Section 2.5 hereof. 
 2.4 Form S-3 Registration. In case
the Company shall receive from any Holder or Holders of Shares a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form registration statement and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders of Shares (the “Initiating Holders”), the Company will: 
 (a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders of Registrable
Securities; and 
 (b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so
requested and as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the
Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20) days after mailing of such written notice from the Company; provided, however, that the Company
shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 
 (i) if Form
S-3 (or any successor or similar form) is not available for such offering by the Initiating Holders, or 
 (ii) if the Initiating
Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than Five
Hundred Thousand Dollars ($500,000), or 
 (iii) if the Company shall furnish to the Initiating Holders a certificate signed by the
Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected
at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than ninety (90) days after receipt of the request of the Initiating Holder or Holders under this
Section 2.4; provided, that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period, or 
 (iv) in any twelve (12) month period, if the Company has already effected two (2) registrations on Form S-3 for any Holders pursuant to this Section 2.4 during such twelve (12) month period,
or 
 (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general
consent to service of process in effecting such registration, qualification or compliance. 
 (c) If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.4 and the Company shall include such information in the

  

 7 

 
written notice referred to in Section 2.4(a). In such event, the right of any Holder to include its Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by the Holders of a majority of the Registrable Securities
held by the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by a majority in interest of the Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 2.4, if the
underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities which would
otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis based on the total purchase price paid to the Company
for the Registrable Securities held by all such Holders (including the Initiating Holders). Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 
 (d) Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the Registrable Securities and other securities so
requested to be registered as soon as practicable after receipt of the request or requests of the holders of Shares. 
 2.5
Expenses Of Registration. Except as specifically provided herein, all Registration Expenses incurred in connection with any registration under Section 2.2, Section 2.3 or Section 2.4 herein shall be borne by the Company. All
Selling Expenses incurred in connection with any registrations hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay
for expenses of any registration proceeding begun pursuant to Section 2.4, the request of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning the
Company of which the Initiating Holders were not aware at the time of such request or (b) the holders of a majority of the Registrable Securities agree to forfeit their right to one requested registration pursuant to Section 2.4, as
applicable, in which event such right shall be forfeited by all holders of Registrable Securities. If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including Registrable
Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to clause (a) above, then the
holders of Shares shall not forfeit their rights pursuant to Section 2.4. 
 2.6 Obligations Of The Company. Whenever
required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a)
Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for up to ninety (90) days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at
any time, upon written notice to the participating Holders and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may delay the filing or effectiveness of any registration statement or suspend
the use or effectiveness of any registration statement (and the 

  

 8 

 
Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if an
executive officer of the Company reasonably determines (which determination shall be confirmed by the Company’s Board of Directors within forty-eight (48) hours) that the Company may, in the absence of such delay or suspension hereunder,
be required under state or federal securities laws to disclose any corporate development the disclosure of which could reasonably be expected to have a serious adverse effect upon the Company, its stockholders, a potentially significant transaction
or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto. No more than two (2) such Suspension Periods shall occur in any twelve (12) month period. In the event that the Company shall
exercise its rights under the preceding sentence, the applicable time period during which the registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period. If so directed by the
Company, the Initiating Holders shall use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Initiating Holders’ possession, of the prospectus relating to such
Registrable Securities current at the time of receipt of such notice. The Company shall not be required to file, cause to become effective or maintain the effectiveness of any registration statement that contemplates a distribution of securities on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 
 (b) Prepare and file with the SEC such amendments
and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered
by such registration statement. 
 (c) Furnish to the Holders such number of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (d) Use all reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue
Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriters of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus
relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company will use reasonable efforts to amend or supplement such prospectus
promptly in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing. 
  

 9 

 (g) Use its best efforts to furnish on the date that such Registrable Securities are delivered to
the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily
given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated as of such date, from the independent certified public
accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and if permitted by applicable
accounting standards, to the Holders requesting registration of Registrable Securities. 
 2.7 Termination of Registration
Rights. All registration rights granted under this Section 2 shall terminate and be of no further force and effect three (3) years after the date of the Company’s Initial Offering. In addition, a Holder’s registration rights
shall expire if (a) the Company has completed its Initial Offering and is subject to the provisions of the Exchange Act; (b) such Holder (together with its affiliates) holds less than one percent (1%) of the Company’s outstanding
Common Stock (treating all shares of convertible Preferred Stock on an as converted basis) and (c) all Registrable Securities held by such Holder (and its affiliates, partners and former partners) may be sold under Rule 144 during any
ninety (90) day period. 
 2.8 Delay of Registration; Furnishing Information. 
 (a) No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any
controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 (b) It shall be a
condition precedent to the obligations of the Company to take any action pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them
and the intended method of disposition of such securities as shall be required to effect the registration of their Registrable Securities. 
 (c) The Company shall have no obligation with respect to any registration requested pursuant to Section 2.4 if, due to the operation of subsection 2.4(c), the number of shares or the anticipated aggregate offering price of the
Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as
specified in Section 2.4. 
 2.9 Indemnification. In the event any Registrable Securities are included in a registration
statement under Sections 2.2, 2.3 or 2.4: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each
Holder, the partners, officers, and directors and legal counsel of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities
Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon any of the 

  

 10 

 
following statements, omissions or violations (collectively a “Violation”) by the Company: (i) any untrue statement or alleged untrue
statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or
regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, officer, director, legal
counsel, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that the indemnity
agreement contained in this Section 2.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such registration by such Holder, partner, officer, director, legal counsel, underwriter or controlling person of such Holder. 
 (b) To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which
such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers, and legal counsel and each person, if any, who controls the Company within the meaning of the Securities
Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors or officers or any person who controls such Holder, against any losses, claims, damages or
liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or controlling person of such other Holder may become subject under the Securities
Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such
Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder
will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, legal counsel, controlling person, underwriter or other Holder, or partner, officer, director, legal counsel or controlling person of such
other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Violation; provided, however, that the indemnity agreement contained in this
Section 2.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld;
provided further, that in no event shall any indemnity under this Section 2.9 exceed the net proceeds from the offering received by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 2.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 2.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof 

  

 11 

 
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with
the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified
party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to
defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may
have to any indemnified party otherwise than under this Section 2.9. 
 (d) If the indemnification provided for in this
Section 2.9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified
party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative
fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided,
that in no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder. 
 (e) The obligations of the Company and Holders under this Section 2.9 shall survive completion of any offering of Registrable Securities in a registration statement and the termination of this Agreement. No Indemnifying Party,
in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 
 2.10
Assignment Of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities which (a) is a
subsidiary, parent, affiliate, related fund, general partner, limited partner or retired partner of a Holder, or (b) to any other Holder, or (c) is a Holder’s family member or trust for the benefit of an individual Holder, or
(d) acquires at least twenty-five thousand (25,000) shares of Registrable Securities (adjusted for stock splits and combinations); provided, however, (A) the transferor shall, within ten (10) days after such transfer,
furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned and (B) such transferee shall agree to be subject to all
restrictions set forth in this Agreement. 
 2.11 Acceptance of Registration Rights. By acceptance of any benefits under this
Section 2, Holders of Registrable Securities hereby agree to be bound by the provisions hereunder. 
  

 12 

 2.12 Limitation On Subsequent Registration Rights. After the date of this Agreement, the
Company shall not, without the prior written consent of the Holders of at least fifty percent (50%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company
that would grant such holder demand registration rights or the right to include such shares in a registration statement that would reduce the number of shares includable by the Holders. However, after the Company becomes a reporting company under
Section 13 or Section 15 of the Exchange Act, the Company may grant demand rights to holders or prospective holders so long as the Holders of Registrable Securities hereunder have the right to include their Registrable Securities in any
such registration without reduction. 
 2.13 “Market Stand-Off” Agreement. Each Holder agrees that during the one
hundred eighty (180) day period following the effective date of a registration statement of the Company filed under the Securities Act the Holder shall not, to the extent requested by the Company and any underwriter, sell, pledge, lend,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any options, right or warrant to purchase, or otherwise transfer or dispose of (other than to donees who agree to be similarly bound), or enter
into any swap, hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock of the Company or any securities convertible into or exercisable or exchangeable for Common Stock held by the Holder at any time during
such period except Common Stock included in such registration; provided, however, that: 
 (a) such agreement shall apply only
to the Company’s Initial Offering; and 
 (b) all officers and directors of the Company enter into similar agreements.

 Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with
the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten
(10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the
Securities Act. The obligations described in this Section 2.13 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration
relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject
to the foregoing restriction until the end of said one hundred eighty (180) day period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by this Section 2.13. The underwriters of the
Company’s stock are intended to be third party beneficiaries of this Section 2.13 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 2.14 Rule 144 Reporting. With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which
may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 
 (a) Make and keep public information available, as those terms are understood and defined in SEC Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first
registration filed by the Company for an offering of its securities to the general public; 
  

 13 

 (b) File with the SEC, in a timely manner, all reports and other documents required of the Company
under the Exchange Act; and 
 (c) So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon request:
a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the most
recent annual or quarterly report of the Company; and such other reports and documents as a Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing it to sell any such securities without registration.

 SECTION 3. COVENANTS. 
 3.1 Basic
Financial Information and Reporting. 
 (a) The Company will maintain true books and records of account in which full and correct
entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied, and will set aside on its books all such proper
accruals and reserves as shall be required under generally accepted accounting principles consistently applied. 
 (b) The Company
will furnish each Major Investor as soon as practicable after the end of each fiscal year of the Company, and in any event within ninety (90) days thereafter, an audited consolidated balance sheet of the Company, as at the end of such fiscal
year, and an audited consolidated statement of income and an audited consolidated statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied and setting forth
in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion thereon by independent public accountants of national standing selected by
the Company’s Board of Directors. 
 (c) The Company will furnish each Major Investor as soon as practicable after the end of
each month, and in any event within thirty (30) days thereafter, an unaudited balance sheet of the Company as of the end of each such month, and an unaudited statement of income and an unaudited statement of cash flows of the Company for such
month and for the current fiscal year to date, including a comparison to plan figures for such period, prepared in accordance with generally accepted accounting principles consistently applied, with the exception that no notes need be attached to
such statements and year-end audit adjustments may not have been made. 
 (d) The Company shall furnish each Major Investor other
information as reasonably requested by such Major Investor; provided, however, that the Company shall not be obligated under this Section 3.1 with respect to a competitor of the Company or with respect to materials or information which
the Board of Directors determines in good faith is confidential and should not, therefore, be disclosed. 
  

 14 

 3.2 Inspection Rights. Each Major Investor holding at least twenty percent (20%) or
more shares of the issued and outstanding Series D Preferred Stock, at least twenty percent (20%) or more shares of the issued and outstanding Series C Preferred Stock, or at least twenty percent (20%) or more shares of the issued and
outstanding Series B Preferred Stock, as applicable, of the Company shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of
its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this
Section 3.2 with respect to a competitor of the Company or with respect to materials or information which the Board of Directors determines in good faith is confidential and should not, therefore, be disclosed. 
 3.3 Confidentiality of Records. 
 (a) Each Investor agrees not to use Confidential Information (as hereinafter defined) of the Company for its own use or for any purpose except to evaluate and enforce its equity investment in the Company. Except as permitted under
subsection (b) below, each Investor agrees to use its reasonable best efforts not to disclose such Confidential Information to any third parties. Each Investor shall undertake to treat such Confidential Information in a manner consistent with
the treatment of its own information of such proprietary nature and agrees that it shall protect the confidentiality of and use reasonable best efforts to prevent disclosure of the Confidential Information to prevent it from falling into the public
domain or the possession of unauthorized persons. Each transferee of any Investor who receives Confidential Information shall agree to be bound by such provisions. For purposes of this Section, “Confidential Information” means any
information, trade secrets, data, or know-how, including, but not limited to, the Company’s patent applications, test or clinical data, licenses, research, products, services, development, inventions, consultants’ or advisors’
identities, samples, processes, designs, engineering, marketing, finances, or business partners disclosed by the Company pursuant to this Agreement. 
 (b) Confidential Information does not include information, technical data or know-how which (i) is in the Investor’s possession at the time of disclosure as shown by Investor’s files and records
immediately prior to the time of disclosure; (ii) before or after it has been disclosed to the Investor, it is part of the public knowledge or literature, not as a result of any action or inaction of the Investor; (iii) is approved for
release by written authorization of Company or (iv) is rightfully disclosed to Investor by a third party without restriction. The provisions of this Section shall not apply (i) to the extent that an Investor is required to disclose
Confidential Information pursuant to any law, statute, rule or regulation or any order of any court or jurisdiction process or pursuant to any direction, request or requirement (whether or not having the force of law but if not having the force of
law being of a type with which institutional investors in the relevant jurisdiction are accustomed to comply) of any self-regulating organization or any governmental, fiscal, monetary or other authority; (ii) to the disclosure of Confidential
Information to an Investor’s employees, counsel, accountants or other professional advisors; (iii) to the extent that an Investor needs to disclose Confidential Information for the protection of any of such Investor’s rights or
interest against the Company, whether under this Agreement or otherwise or (iv) to the disclosure of Confidential Information to a prospective transferee of securities which agrees to be bound by the provisions of this Section in
connection with the receipt of such Confidential Information. 
  

 15 

 3.4 Reservation of Common Stock. The Company will at all times reserve and keep available,
solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 
 3.5 Proprietary Information and Inventions Agreement. The Company shall require all employees and consultants who have access to proprietary information of the Company to enter into agreements in the Company’s standard
form providing for the protection of proprietary information and inventions. 
 3.6 Use of Proceeds. The proceeds from the
issuance and sale of the Series D Stock pursuant to the Purchase Agreement (the “Proceeds”) shall be used by the Company for research and development for the Axxess stent and related delivery system and improvements thereon, working
capital and other general corporate purposes. 
 3.7 Assignment of Right of First Refusal. In the event the Company elects not to
exercise any right of first refusal or right of first offer the Company may have with respect to a proposed transfer of any of the Company’s outstanding capital stock pursuant to the Company’s charter documents or by-laws, by contract or
otherwise, the Company shall, to the extent it may do so, assign such right of first refusal or right of first offer to the Series D Investors and Series C Investors. In the event of such assignment, each Series D Investor and each Series
C Investor shall have a right to purchase its pro rata portion of the capital stock proposed to be transferred. Each Series D Investor’s and Series C Investor’s pro rata portion shall be equal to the product obtained by multiplying
(i) the aggregate number of shares proposed to be transferred by (ii) a fraction, the numerator of which is the number of shares of Registrable Securities held by such Series D Investor or Series C Investor, as applicable, at the time
of the proposed transfer and the denominator of which is the total number of shares owned by all Series D Investors and Series C Investors at the time of such proposed transfer. Any shares not so purchased shall be reallocated to all
fully-exercising Series D Investors and Series C Investors on a pro rata basis until all such shares are purchased and no Series D Investors or Series C Investors desire to purchase additional shares. 
 3.8 Directors’ Liability and Indemnification. The Company’s Certificate of Incorporation and bylaws shall provide (a) for
elimination of the liability of the directors to the maximum extent permitted by law and (b) indemnification of directors for acts on behalf of the Company to the maximum extent permitted by law. 
 3.9 Termination of Covenants. All covenants of the Company contained in this Section 3 shall expire and terminate as to each Investor
upon the earlier of (i) the effective date of the registration statement pertaining to the Initial Offering in which all of the Preferred Stock is converted into Common Stock or (ii) upon an Acquisition or Asset Transfer (each as defined
in the Company’s Fifth Amended and Restated Certificate of Incorporation). 
 SECTION 4. RIGHTS OF FIRST REFUSAL. 
 4.1 Subsequent Offerings. Each Series D Investor and each Prior Investor and Occam, shall have a right of first refusal to purchase its
pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity Securities excluded by Section 4.6 hereof. However, a
holder of Series A Preferred shall only have the foregoing right if, and to the extent, such holder has converted its shares of Series A Preferred into Common Stock (with such holdings of such Common 

  

 16 

 
Stock only being used for determinations of pro rata share hereunder). Each Series D Investor’s and each Prior Investor’s pro
rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including any shares of Common Stock issued or issuable upon conversion of the Shares held by such Series D Investor or Prior Investor)
held immediately prior to the issuance of such Equity Securities by such Series D Investor or Prior Investor to (b) the total number of shares of the Company’s outstanding Common Stock (including all shares of Common Stock issued or
issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities. Occam’s pro rata share is equal to the ratio of (a) the number of shares
of the Company’s Common Stock (including any shares of the Company’s Common Stock that are issuable upon exercise of warrants held by Occam) held by Occam, immediately prior to the issuance of such Equity Securities, as a result of the
exercise of warrants held by it to (b) the total number of shares of the Company’s outstanding Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding
warrants or options) immediately prior to the issuance of the Equity Securities. The term “Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security
convertible, with or without consideration, into any Common Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase
any Common Stock, Preferred Stock or other security or (iv) any such warrant or right. 
 4.2 Exercise of Rights. If the
Company proposes to issue any Equity Securities, it shall give each Series D Investor, each Prior Investor and Occam written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the
Company proposes to issue the same. Each Series D Investor, each Prior Investor and Occam shall have fifteen (15) days from the giving of such notice to agree to purchase its pro rata share of the Equity Securities for the price and
upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell
such Equity Securities to any Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale. 
 4.3 Issuance of Equity Securities to Other Persons. The Company shall have ninety (90) days thereafter to sell the Equity Securities in respect of which the Series D Investor’s, the Prior
Investor’s and Occam’s rights were not exercised, at a price and upon general terms and conditions no more favorable to the purchasers thereof than specified in the Company’s notice to the Investors pursuant to Section 4.2
hereof. If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue or sell any Equity Securities, without first offering such securities
to the Series D Investors, the Prior Investors and Occam in the manner provided above. 
 4.4 Termination and Waiver of Rights
of First Refusal. The rights of first refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to the Company’s Initial
Offering in which all of the Preferred Stock is converted into Common Stock or (ii) an Acquisition. The rights of first refusal established by this Section 4 may be amended, or any provision waived with the written consent of Series D
Investors and Prior Investors holding a majority of the Registrable Securities owned by Series D Investors and Prior Investors, or as permitted by Section 5.7. 
  

 17 

 4.5 Transfer of Rights of First Refusal. The rights of first refusal of each Investor under
this Section 4 may be transferred to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.10. 
 4.6 Excluded Securities. The rights of first refusal established by this Section 4 shall have no application to any Equity Securities which would not be considered “Additional Shares of Common
Stock” as defined in Section E(4)(i)(v) of Article IV of the Company’s Fifth Amended and Restated Certificate of Incorporation and any shares of Common Stock issued in connection with any stock split, stock dividend or
recapitalization of the Company. 
 SECTION 5. MISCELLANEOUS. 
 5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed entirely
within Delaware. 
 5.2 Survival. The representations, warranties, covenants, and agreements made herein shall survive any
investigation made by any Holder and the closing of the transactions contemplated hereby. All statements as to factual matters contained in any certificate or other instrument delivered by or on behalf of the Company pursuant hereto in connection
with the transactions contemplated hereby shall be deemed to be representations and warranties by the Company hereunder solely as of the date of such certificate or instrument. 
 5.3 Successors And Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable Securities from time to time; provided,
however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem and treat the person listed as the holder of
such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 
 5.4 Entire Agreement. This Agreement, the agreements under which the Holders acquired the Shares, and the Exhibits thereto constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein and therein 
 5.5 Aggregation of Stock. All Registrable Securities held or acquired by affiliated entities or persons or persons or entities under common
management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 5.6 Severability. In case any provision of the Agreement shall be invalid, illegal, or unenforceable, the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

  

 18 

 5.7 Amendment And Waiver. 
 (a) Except as otherwise expressly provided, this Agreement may be amended or modified only upon the written consent of the Company and the holders
of at least fifty percent (50%) of the Shares, provided that such holders include holders of at least fifty percent (50%) of the shares of Series D Preferred Stock and holders of at least fifty percent (50%) of the shares of
Series C Preferred Stock, provided further that such amendment be approved by the holders of at least fifty percent (50%) of the Common Stock held by the Common Holders if such amendment relates to Section 2 of this Agreement and
would adversely change the rights or obligations of such Common Holders in a manner materially different than all other Holders of Registrable Securities. 
 (b) Except as otherwise expressly provided, the obligations of the Company and the rights of the Holders under this Agreement may be waived only with the written consent of the holders of at least fifty percent
(50%) of the Shares, provided that such holders include holders of at least fifty percent (50%) of the shares of Series D Preferred Stock and holders of at least fifty percent (50%) of the shares of Series C Preferred Stock,
provided further that such waiver be approved by the holders of at least fifty percent (50%) of the Common Stock held by the Common Holders if such waiver relates to Section 2 of this Agreement and would waive the rights of such
Common Holders in a manner materially different than all other Holders of Registrable Securities. 
 5.8 Delays Or Omissions.
It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any Holder, upon any breach, default or noncompliance of the Company under this Agreement shall impair any such right, power, or remedy, nor shall it be
construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any
kind or character on any Holder’s part of any breach, default or noncompliance under the Agreement or any waiver on such Holder’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the
extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to Holders, shall be cumulative and not alternative. 
 5.9 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal
delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient; if not, then on the next business day or (c) one (1) day after deposit with a globally
recognized overnight courier, specifying next day delivery, with written verification of receipt. 
 5.10 Attorneys’ Fees.
In the event that any dispute among the parties to this Agreement should result in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such
prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 5.11 Titles And Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not
to be considered in construing this Agreement. 
  

 19 

 5.12 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be an original, but all of which together shall constitute one instrument. 
 5.13 Additional Investors.
Notwithstanding anything to the contrary contained herein, if the Company shall issue Equity Securities in accordance with Section E(4)(i)(v)(D)-(J) of Article IV of the Company’s Fifth Amended and Restated Certificate, any
purchaser of such Equity Securities may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder.

 5.14 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated
herein. Such amendment and restatement is effective upon the execution of the Agreement by the Company and by the holders of a majority of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock outstanding as of the
date of this Agreement, voting as a single class. Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and terminated in their entirety and shall have no further force and
effect. 
 [signatures on following pages] 
  

 20 

 IN WITNESS WHEREOF, the parties hereto have executed this THIRD AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 
  

			
	COMPANY:
	
	DEVAX, INC.
		
	By:	 	 /s/ Jeffrey Thiel

		 	 Jeffrey Thiel,
 President and CEO

	
	COMMON HOLDERS:
	
	 /s/ Rick Buchholz

	Rick Buchholz
	
	COOLEY GODWARD LLP
		
	By:	 	 /s/ Illegible Signature

	Its:	 	  

	
	 /s/ Jean-Denis Cornillot

	Jean-Denis Cornillot
	
	 /s/ Theresa L. Gavin

	Theresa L. Gavin
	
	R.H. TRUST
		
	By:	 	 /s/ Illegible Signature

	Its:	 	  

	
	 /s/ Jacques Seguin

	Jacques Seguin

  

 21 

					
		
	 /s/ David A. Teicher
	 	
	David A. Teicher	 	
		
	ROBERTS MITANI, LLC	 	
			
	By:	 	 /s/ Illegible Signature
	 	
	Its:	 	  
	 	
		
	 /s/ Georg Bortlein
	 	
	Georg Bortlein	 	
		
	INVESTORS:	 	
		
	HBM BIOVENTURES (CAYMAN) LTD.	 	
			
	By:	 	 /s/ John Arnold
	 	
	Its:	 	Chairman and Managing Director	 	
		
	 INTERNATIONAL BM BIOMEDICINE
 HOLDINGS (CAYMAN) LTD.
	 	
			
	By:	 	 /s/ John Arnold
	 	
	Its:	 	Director	 	
		
	J.A.I.C. – HENSON MEDFOCUS FUND I	 	
			
	By:	 	 /s/ David M. Richards
	 	
	Its:	 	Chief Financial Officer	 	
		
	J.A.I.C. – HENSON MEDFOCUS FUND II	 	
			
	By:	 	 /s/ David M. Richards
	 	
	Its:	 	Chief Financial Officer	 	
		
	WHI MORULA FUND, LLC	 	
			
	By:	 	 /s/ Michael S. Resnick
	 	
	Its:	 	 Executive Vice President; William Harris
 Investors, Inc., Manager
	 	

  

 22 

			
	PRIVATE LIFE BIOMED AG
		
	By:	 	 /s/ Signatures Illegible

	Its:	 	Managing Directors
	
	ALSTERTOR PRIVATE LIFE GMBH & CO. KG
		
	By:	 	 /s/ Signatures Illegible

	Its:	 	  

	
	AQUA CAPITAL PARTNERS, LLC
		
	By:	 	 /s/ Signatures Illegible

	Its:	 	  

	
	CHAUSSON FINANCE
		
	By:	 	 /s/ Signatures Illegible

	Its:	 	  

	
	 /s/ Arthur Cohen

	Arthur Cohen
	
	 /s/ Michel de Guilhermier

	Michel de Guilhermier
	
	 /s/ Vigdis Erklef

	Vigdis Erklef
	
	 /s/ Raul Esquivel

	Raul Esquivel
	
	 /s/ Benoit Galland

	Benoit Galland

  

 23 

			
	GLOBAL DAMON PHARM
		
	By:	 	 /s/ O.K. Kim

	Its:	 	President and Chief Executive Officer
	
	OCI, LTD
		
	By:	 	 /s/ L. Leggat Smith             /s/ S.
Postriteri

	Its:	 	Directors
	
	 /s/ Herve Hales

	Herve Hales
	
	HENSON FAMILY TRUST & MICHAEL HENSON
		
	By:	 	 /s/ Michael Henson

	Its:	 	Trustee
	
	 /s/ Jonathan Ilany

	Jonathan Ilany
	
	 /s/ Jean Marsac

	Jean Marsac
	
	OCEAN STRATEGIC HOLDINGS LIMITED
		
	By:	 	 /s/ Signature Illegible

	Its:	 	  

	
	R.H. TRUST
		
	By:	 	 /s/ Signatures Illegible

	Its:	 	  

	
	 /s/ Bruce Roberts

	Bruce Roberts

  

 24 

			
	 /s/ John Sites

	John Sites
	
	 /s/ Franz N. Tudor

	Franz N. Tudor
	
	INTERWEST PARTNERS IX, L.P.
	
	By: INTERWEST MANAGEMENT PARTNERS IX, LLC, its General Partner
		
	By:	 	 /s/ Michael Sweeney

	Name:	 	Michael Sweeney
	Title:	 	Managing Director
	
	OCCAM INTERNATIONAL B.V.
		
	By:	 	 /s/ Signature Illegible

	Its:	 	Director
	
	BIO-STAR PRIVATE EQUITY FUND LLC
		
	By:	 	 /s/ David M. Richards

	Its:	 	Chief Financial Officer
	
	BIO-STAR PRIVATE EQUITY FUND FP LLC
		
	By:	 	 /s/ David M. Richards

	Its:	 	Chief Financial Officer
	
	PIPER JAFFRAY & CO.
		
	By:	 	 /s/ R.N. Dolan

	Its:	 	CAO-CIS Division
	
	 U.S. VENTURE PARTNERS IX, L.P.
 By
Presidio Management Group IX, L.L.C.
 Its General Partner

		
	By:	 	 /s/ Michael P. Maher

		 	Michael P. Maher
		 	Attorney-In-Fact

  

 25 

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (DAPER I)
	
	 /s/ Tyler Edelstein

	By:	 	Tyler Edelstein
	Its:	 	Managing Director- Separate Investments
	
	 /s/ James H. Dahl

	James H. Dahl
	
	DAHL FAMILY FOUNDATION, INC.
		
	By:	 	 /s/ William Dahl

	Its:	 	Vice President
	
	DAHL CHILDREN TRUST: FBO JAMES A. DAHL
		
	By:	 	 /s/ William Dahl

	Its:	 	Trustee
	
	DAHL CHILDREN TRUST: FBO KATHRYN W. DAHL
		
	By:	 	 /s/ William Dahl

	Its:	 	Trustee
	
	L3 HOLDINGS, LLC.
		
	By:	 	 /s/ Signature Illegible

	Its:	 	Agent
	
	FARGO INVESTMENTS, L.P.
		
	By:	 	 /s/ Bradford M. Freeman

	Its:	 	Bradford M. Freeman, General Partner
	
	 /s/ Paul Vance

	Paul Vance

  

 26 

			
	
	 /s/ David M. Seldin

	David M. Seldin
	
	 /s/ Irving Roberts

	Irving Roberts
	
	 /s/ Steve Umberger

	Steve Umberger
	
	LEARNING TECH LTD. TARGET BENEFIT & PENSION PLAN & TRUST: FBO HERBERT W. SCHEIDEL
		
	By:	 	 /s/ H. Scheidel

	Its:	 	Trustee
	
	POLYIDUS PARTNERS, L.P.
		
	By:	 	 /s/ Signature Illegible

	Its:	 	Vice President and Chief Financial Officer
	
	 /s/ Jeffrey Meyer

	Jeffrey Meyer
	
	MILLER, MILLER, BRADWISH & MILLER PROFIT SHARING PLAN & TRUST FBO RICHARD E. MILLER, JR.
		
	By:	 	 /s/ Signature Illegible

	Its:	 	Trustee
	
	SCOTT & DEBORAH MILLER FAMILY TRUST 9/17/2004
		
	By:	 	 /s/ Signature Illegible

	Its:	 	Trustee
	
	 /s/ Charles W. Newman

	Charles W. Newman

  

 27 

			
	 /s/ Andy Crawford

	Andy Crawford
	
	PAM AND TIM FITCH
		
	By:	 	 /s/ Pam Fitch                 /s/ Tim
Fitch

  

 28 

 EXHIBIT A 
 SCHEDULE OF COMMON HOLDERS 
  

			
	 NAME
	  	COMMON STOCK
	 Rick Buchholz
	  	5,000
	 Cooley Godward LLP
	  	25,000
	 Jean-Denis Cornillot
	  	15,000
	 Theresa L. Gavin
	  	20,000
	 R.H. Trust
	  	62,000
	 Jacques Seguin
	  	1,750,000
	 David A. Teicher
	  	20,000
	 Roberts Mitani, LLC
	  	8,500
	 Georg Bortlein
	  	67,500

 EXHIBIT B 
 SCHEDULE OF INVESTORS 
  

									
	 NAME
	  	SERIES A	  	SERIES B	  	SERIES C	  	SERIES D
	 HBM BioVentures (Cayman) Ltd.
	  		  		  	1,760,965	  	1,475,777
	 International BM Biomedicine Holdings (Cayman) Ltd.
	  		  	844,595	  	425,343	  	915,001
	 J.A.I.C. – Henson Medfocus Fund I
	  		  	84,460	  	85,474	  	79,575
	 J.A.I.C. – Henson Medfocus Fund II
	  		  		  		  	79,575
	 Rock Creek Partners II, Ltd.
	  		  	896,436	  	430,920	  	
	 WHI Morula Fund, LLC
	  		  		  	84,459	  	58,741
	 Private Life BioMed AG
	  		  		  	219,595	  	158,220
	 Alstertor Private Life GmbH & Co. KG
	  		  		  	33,784	  	24,342
	 Aqua Capital Partners, LLC
	  		  	25,719	  		  	
	 Chausson Finance
	  	56,980	  		  		  	
	 Arthur Cohen
	  	74,074	  		  		  	
	 Michel de Guilhermier
	  	96,866	  		  		  	
	 Vigdis Erklef
	  	18,518	  	8,492	  		  	
	 Raul Esquivel
	  	74,074	  		  		  	
	 Benoit Galland
	  	34,188	  		  		  	
	 Global Damon Pharm
	  		  	168,919	  		  	
	 OCI, Ltd.
	  	55,556	  		  		  	
	 Herve Hales
	  	34,188	  		  		  	
	 Henson Family Trust & Michael Henson
	  		  	16,892	  		  	13,500
	 Jonathan Ilany
	  	37,100	  		  		  	
	 Jean Marsac
	  	111,111	  	10,401	  		  	
	 Ocean Strategic Holdings Limited
	  		  	6,858	  		  	
	 R.H. Trust
	  	222,222	  	18,915	  		  	
	 Bruce Roberts
	  		  	10,482	  		  	
	 John Sites
	  	81,676	  		  		  	79,576
	 Franz N. Tudor
	  	7,407	  		  		  	
	 InterWest Partners IX, L.P.
	  		  		  		  	2,228,117
	 Occam International B.V.
	  		  		  		  	457,867
	 Bio-Star Private Equity Fund LLC
	  		  		  		  	89,921
	 Bio-Star Private Equity Fund FP LLC
	  		  		  		  	16,180
	 U.S. Ventures IX, L.P.
	  		  		  		  	2,221,485
	 The Board of Trustees of the Leland Stanford Junior University (DAPER I)
	  		  		  		  	6,631
	 James H. Dahl
	  		  		  		  	26,525
	 Dahl Family Foundation, Inc.
	  		  		  		  	26,525
	 Dahl Children Trust: FBO James A. Dahl
	  		  		  		  	39,788
	 Dahl Children Trust: FBO Kathryn W. Dahl
	  		  		  		  	39,788
	 L3 Holdings, LLC
	  		  		  		  	59,682
	 Pam and Tim Fitch
	  		  		  		  	19,894
	 Fargo Investments, L.P.
	  		  		  		  	79,576
	 Paul Vance
	  		  		  		  	6,631

  

 B-1 

									
	 NAME
	  	SERIES A	  	SERIES B	  	SERIES C	  	SERIES D
	David M. Seldin	  		  		  		  	39,788
	Irving Roberts	  		  		  		  	26,525
	Steve Umberger	  		  		  		  	26,525
	Learning Tech. Ltd. Target Benefit & Pension Plan & Trust FBO Herbert W. Scheidel	  		  		  		  	26,525
	Polyidus Partners, LP (Pete Thomas)	  		  		  		  	26,525
	Jeffrey Meyer	  		  		  		  	26,525
	Miller, Miller, Bradwish & Miller Profit Sharing Plan & Trust FBO Richard E. Miller, Jr.	  		  		  		  	13,263
	Scott and Deborah Miller Family Trust 9/17/2004	  		  		  		  	26,525
	Charles W. Newman	  		  		  		  	19,894
	Andy Crawford	  		  		  		  	53,050

  

 B-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]